Improving Health Outcomes With Kefir
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age24-70
SponsorUniversity of Alberta
About this trial
The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.
Eligibility criteria
Qualifiers
females and males (24-70 years old) living in Edmonton (or Edmonton area/driving distance);
overweight or obesity (BMI >25 Caucasian, >23 Asian);
at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol/L or/and HbA1C ≥ 5.5 - 6.4%); or
with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol/L or/and HbA1C ≥ 6.5%).
Disqualifiers
a usual high intake (maximum intake 3 servings/week) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months;
gastrointestinal (GI) disorders of any kind;
being pregnant or breastfeeding;
monogenic dyslipidemias and endocrine disorders except for diabetes;
Trial design
Treatments tested in this trial
- Traditional Kefir
- Milk (placebo)
Treatment groups
156 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov